Risk-efficacy balance of ulipristal acetate compared to surgical alternatives.

Mei-An MiddelkoopPierre M BetJoost P H DrenthJudith A F HuirneWouter J K Hehenkamp

Published in: British journal of clinical pharmacology (2021)

The DILI risk of ulipristal is considerably lower than that of other medicines that are not suspended, nor need additional safety measures. When evaluating drugs and drug safety, risks that apply to the alternative nonpharmacological treatment options should be taken into consideration.

Keyphrases

drug induced
emergency department
climate change
breast cancer risk